Can a vaccine stop cancer coming back?

What the report says

The Observer reports that a biotechnology effort in Uganda is pursuing experimental cancer-vaccine technologies aimed at lowering the risk that cancer will return after treatment. The work is being led by Dr Matthias Magoola, founder of Dei BioPharma, and was described in seven US patent applications filed between August 18 and August 25 with the US Patent and Trademark Office. The filings focus on messenger RNA, or mRNA, vaccine concepts that would train the immune system to recognize molecular changes linked to certain cancers.

According to the article, the proposed targets include abnormalities associated with some forms of leukaemia, brain cancer, acute myeloid leukaemia, RAS-mutant tumours, a TP53 mutation, and cancers tied to HPV16/18. The idea is not a single universal shot, but a set of vaccine candidates matched to the biology of a patient’s tumour, and in some cases to immune-system features such as HLA type. The article notes that the approach reflects a shift from classifying cancers only by where they occur to identifying what is driving them at the molecular level.

The Observer emphasizes that this remains early-stage research. A patent filing does not mean the vaccines are approved, proven safe, or available to patients. Still, the effort is notable because it shows advanced cancer-vaccine development taking shape from a Ugandan biotech programme at a time of broad international interest in mRNA medicine. The article says the concept may be especially relevant after standard treatment, when tiny numbers of cancer cells can remain and later cause recurrence.